A Year in Review
Dr. Jack Cush, Philadelphia
Differences in Clinical Presentation and Outcomes of Early vs Late Onset PsA
Dr. Olga Petryna, New York
Abstract 0377
mTORC1 as a Driver of Inflammation in sJIA Connecting Pathogens of sJIA and MAS
Dr. Olga Petryna, New York
Abstract 0004
Patient Reported Outcomes in PsA Using Novel IL 17A Inhibitor
Dr. Sims discusses abstract 0199 presented at ACR22 Convergence in Philadelphia, PA.
Abstract 0199: Izokibep, a Novel IL-17A Inhibitor, Improves Patient-reported Outcomes – 16-Week Results from a Placebo-controlled Phase 2 Study in Patients with Active Psoriatic Arthritis
The CONSUL Trial
Dr. Sheila Reyes, The Phillipines
Abstract 0526
Predicting Palindromic Prognosis
A Step Closer to Identifying Phenotypes of RA ILD
Top 3 Messages About JAK Inhibitor Safety
Pain in RA: Different Drugs for Different Mechanisms
Giant Cell Arteritis and Polymyalgia Rheumatica Update
JAK Inhibitors for New Indications
Top 3 Messages About JAK Inhibitor Safety
Pain in RA: Different Drugs for Different Mechanisms
JAK Inhibitors for New Indications
Potential of Radiomics to Predict TNF Therapy Outcomes in axSpA
Treat to Target Outcomes in Early AxSpA
Does Telemonitoring in SpA Work?
PsA Treatment: is Earlier Better?
JAK Inhibitors for New Indications
Transition from Psoriasis to PsA: Can we Prevent It?
EULAR 2024 Daily Recap - Days 1 & 2
Mechanistic Promise in RA Doesn’t Always Mean Actual Gain
The Role of Psychosocial Determinants in the Management of Rheumatoid Arthritis
Do we need more IL-17 and JAK Inhibitors in Spondyloarthritis?
Voclosporin and Steroids in Lupus Nephritis
Create your
podcast in
minutes
It is Free
Good Mood Revolution
Good Nurse Bad Nurse
The Relaxback UK Show
On Call With Dr. Anselm Anyoha
The Doctor’s Farmacy with Mark Hyman, M.D.
The Peter Attia Drive